Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Tegafur is an orally bioavailable prodrug form of 5-fluorouracil (5-FU; Item No. 14416).1 It is converted to 5-FU in vivo enzymatically or by cytochrome P450 oxidation. Tegafur inhibits proliferation of HT-29, BxPC-3, and Panc02 cells (IC50s = 201, 172, and 179 µM, respectively).2 It also reduces tumor growth in an HT-27 colon carcinoma mouse xenograft model when administered at a dose of 50 mg/kg and in a 4-1ST gastric carcinoma mouse xenograft model when used in combination with uracil.2,3 Formulations containing tegafur, in combination with uracil, have been used in the treatment of cancer.
WARNING This product is not for human or veterinary use.
1. Metabolic activation of R,S-
2. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties. J. Med. Chem. 51(2), 314-323 (2008).
3. Amrubicin, a novel 9-